The UK Dementia Research Institute welcomes you to a virtual roundtable to discuss the promising Phase III trial data of lecanemab for the treatment of Alzheimer’s disease, following presentation of results from Eisai/Biogen at CTAD (Clinical Trials on Alzheimer' Disease conference - Nov 29).
An expert panel of clinicians and basic researchers will dig into the data, providing their perspective on what the results mean for amyloid therapies, drug discovery, trial design, the next steps and more.
- Dr Catherine Mummery
- Prof James Rowe
- Prof Bart De Strooper
- Prof Clare Mackay
Chaired by Prof Jonathan Schott & and Dr Giovanna Lalli
Following panellist presentations, there will be an opportunity for audience Q&A and discussion.
The roundtable is intended for an audience of discovery scientists, clinicians, industry and experts in dementia research and drug development field.
Register now for the webinar taking place on Tuesday 13 December 2022,
16:00 – 17:30 (GMT)
17:00 – 18:30 (CET)
11:00 – 12:30 (EST)
08:00 – 09:30 (PST)